Your browser doesn't support javascript.
loading
Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells.
Sledzinska, Anna; Vila de Mucha, Maria; Bergerhoff, Katharina; Hotblack, Alastair; Demane, Dafne Franz; Ghorani, Ehsan; Akarca, Ayse U; Marzolini, Maria A V; Solomon, Isabelle; Vargas, Frederick Arce; Pule, Martin; Ono, Masahiro; Seddon, Benedict; Kassiotis, George; Ariyan, Charlotte E; Korn, Thomas; Marafioti, Teresa; Lord, Graham M; Stauss, Hans; Jenner, Richard G; Peggs, Karl S; Quezada, Sergio A.
Afiliação
  • Sledzinska A; Cancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
  • Vila de Mucha M; Cancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Regulatory Genomics Research Group, UCL Cancer Institute, University College London, London WC1E 6DD, UK.
  • Bergerhoff K; Cancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
  • Hotblack A; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
  • Demane DF; Cancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
  • Ghorani E; Cancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
  • Akarca AU; Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
  • Marzolini MAV; Cancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
  • Solomon I; Cancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
  • Vargas FA; Cancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
  • Pule M; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
  • Ono M; Faculty of Natural Sciences, Department of Life Sciences, Imperial College London, London SW7 2BB, UK.
  • Seddon B; Institute of Immunity and Transplantation, Department of Immunology, Royal Free Hospital, London NW3 2PF, UK.
  • Kassiotis G; Retroviral Immunology Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
  • Ariyan CE; Memorial Sloan Kettering Center, 1275 York Avenue, New York, NY 10065, USA.
  • Korn T; Department of Experimental Neuroimmunology, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany.
  • Marafioti T; Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
  • Lord GM; Faculty of Biology, Medicine and Health, University of Manchester, 46 Grafton Street, Manchester M13 9NT, UK.
  • Stauss H; Institute of Immunity and Transplantation, Department of Immunology, Royal Free Hospital, London NW3 2PF, UK.
  • Jenner RG; Regulatory Genomics Research Group, UCL Cancer Institute, University College London, London WC1E 6DD, UK.
  • Peggs KS; Cancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK. Electronic address: k.peggs@ucl.ac.uk.
  • Quezada SA; Cancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK. Electronic address: s.quezada@ucl.ac.uk.
Immunity ; 52(1): 151-166.e6, 2020 01 14.
Article em En | MEDLINE | ID: mdl-31924474
In addition to helper and regulatory potential, CD4+ T cells also acquire cytotoxic activity marked by granzyme B (GzmB) expression and the ability to promote rejection of established tumors. Here, we examined the molecular and cellular mechanisms underpinning the differentiation of cytotoxic CD4+ T cells following immunotherapy. CD4+ transfer into lymphodepleted animals or regulatory T (Treg) cell depletion promoted GzmB expression by tumor-infiltrating CD4+, and this was prevented by interleukin-2 (IL-2) neutralization. Transcriptional analysis revealed a polyfunctional helper and cytotoxic phenotype characterized by the expression of the transcription factors T-bet and Blimp-1. While T-bet ablation restricted interferon-γ (IFN-γ) production, loss of Blimp-1 prevented GzmB expression in response to IL-2, suggesting two independent programs required for polyfunctionality of tumor-reactive CD4+ T cells. Our findings underscore the role of Treg cells, IL-2, and Blimp-1 in controlling the differentiation of cytotoxic CD4+ T cells and offer a pathway to enhancement of anti-tumor activity through their manipulation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T Reguladores / Proteínas com Domínio T / Granzimas / Fator 1 de Ligação ao Domínio I Regulador Positivo / Neoplasias Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T Reguladores / Proteínas com Domínio T / Granzimas / Fator 1 de Ligação ao Domínio I Regulador Positivo / Neoplasias Idioma: En Ano de publicação: 2020 Tipo de documento: Article